Tesamorelin – 10 mg
Tesamorelin – 10 mg Tesamorelin (e.g., Egrifta SV, Egrifta WR) is an FDA-approved injectable prescription, often supplied in multi-dose kits, used to reduce excess visceral adipose tissue in HIV-infected adults with lipodystrophy. It is not for weight loss. Common side effects include injection site reactions, joint pain, and headache.
Research Use Only Disclaimer
FOR RESEARCH USE ONLY This product is not intended for human or animal use.Not for medical, diagnostic, therapeutic, metabolic, endocrine, fat-related, or consumption purposes.No dosage, administration, or biological outcome claims are made or implied.Use is restricted to qualified laboratory research environments only.
❓Frequently Asked Questions
Is tesamorelin approved for visceral fat or metabolic use?
No. This peptide is supplied strictly for laboratory research purposes.
Does this product include a Certificate of Analysis (COA)?
Yes. Every batch includes a third-party verified COA.
Why is tesamorelin supplied in a 10 mg research format?
This quantity supports analytical testing, stability studies, and reference evaluation, not application or use.
Can this compound be used in humans or animals?
No. It is not approved for use in living systems.
How is this product classified?
It is classified solely as a research peptide, not a drug, supplement, or therapeutic agent.